COVID-19 vaccine

Novavax Revenue Guidance Does Little to Change Neutral Stance on the Stock

By Shanthi Rexaline
NVAX stock continues to languish for want of evidence for a sustainable fundamental improvement. The 2022 revenue guidance issued by the company did stir some optimism, but investors have quickly fallen back to their guarded stance.

Novavax Can Still Find Growth Opportunities Abroad

By Louis Navellier and the InvestorPlace Research Staff
NVAX stock has been listless in 2021, which is frustrating investors. Yet, Novavax is making headway on the international regulatory front.

Novavax Just Caught a Big Break

By Will Ashworth, InvestorPlace Contributor
Politico’s article about Novavax’s inability to manufacture its Covid-19 vaccine wasn't good for NVAX stock. Down 16% since, should you buy?

Blockchain: How This Next Great Tech Platform Could Help Fight COVID-19

By InvestorPlace Research Staff
Simply put, blockchain is the safest way to store and transfer information ever created, which makes it ideal for tracking vaccines.

Biotech Boom: The Race for COVID-19 Vaccines

By InvestorPlace Research Staff
The pandemic highlights how far medical science has come. It also highlights how exciting the future is. While the Year of Biotech has been outstanding so far, we’re only seeing the beginning of a revolution.

Be Careful with Novavax and the Recent Surge in NVAX Stock

By Luke Lango, InvestorPlace Senior Investment Analyst
Covid-19 vaccine stocks are on fire, but many of them appear to be out over their skis, including the group's hottest name, NVAX stock.

7 Red-Hot Vaccine Stocks Racing to Develop a Coronavirus Cure

By Luke Lango, InvestorPlace Senior Investment Analyst
A race to develop a coronavirus vaccine is on, and these red-hot Covid-19 vaccine stocks are leading the way.

Bullish Play on Inovio as it Develops COVID-19 Vaccine

By Ken Trester
The major indexes continue to rally. Take advantage by using a bullish position on Inovio Pharmaceuticals, Inc. (NASDAQ:INO).